Skip to main content
SpringerLink
Log in

Management Strategies for Sexual Health After Breast Cancer Diagnosis

  • Chapter
  • First Online:
Essentials of Menopause Management

  • 1006 Accesses

Abstract

A 48-year-old female presents to the office complaining of vaginal dryness and painful intercourse. Her past medical history is significant for an estrogen receptor-positive breast cancer treated surgically 6 months ago. She is currently on tamoxifen for endocrine therapy. Her last menstrual period was 4 months ago, and over the past 4 months, she has experienced moderate hot flashes and trouble sleeping due to night sweats for which she initiated gabapentin with significant benefit. She notes that her personal life and relationship is being affected by the vaginal symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Park ER, Norris RL, Bober SL. Sexual health communication during cancer care: barriers and recommendations. Cancer J. 2009;15(1):74–7.

    Article  PubMed  Google Scholar 

  2. Kesson EM, Allardice GM, George WD, Burns HJG, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012;344, e2718.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Fobair P, Stewart SL, Chang S, D’Onofrio C, Banks PJ, Bloom JR. Body image and sexual problems in young women with breast cancer. Psychooncology. 2006;15(7):579–94.

    Article  PubMed  Google Scholar 

  5. Bloom JR, Stewart SL, Chang S, Banks PJ. Then and now: quality of life of young breast cancer survivors. Psychooncology. 2004;13(3):147–60.

    Article  PubMed  Google Scholar 

  6. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24(36):5769–79.

    Article  CAS  PubMed  Google Scholar 

  7. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol. 2005;23(8):1736–50.

    Article  CAS  PubMed  Google Scholar 

  8. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17(9):2659–69.

    Article  CAS  PubMed  Google Scholar 

  9. Ferrell BR, Dow KH, Leigh S, Ly J, Gulasekaram P. Quality of life in long-term cancer survivors. Oncol Nurs Forum. 1995;22(6):915–22.

    CAS  PubMed  Google Scholar 

  10. Shamspour N, Assari S, Moghana Lankarani M. Relation between sexuality and health-related quality of life. In: Handbook of disease burdens and quality of life measures. New York: Springer; 2010. p. 3457–73.

    Chapter  Google Scholar 

  11. Male DA, Fergus KD, Cullen K. Sexual identity after breast cancer: sexuality, body image, and relationship repercussions. Curr Opin Support Palliat Care [Internet]. 2015; Available from: http://dx.doi.org/10.1097/SPC.0000000000000184.

  12. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537–44.

    Article  CAS  PubMed  Google Scholar 

  13. Association AP, Association AP, Others. Diagnostic and statistical manual of mental health disorders. Washington, D.C: American Psychiatric Association; 1994.

    Google Scholar 

  14. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol. 1998;16(2):501–14.

    Article  CAS  PubMed  Google Scholar 

  15. Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst. 2004;96(5):376–87.

    Article  PubMed  Google Scholar 

  16. Hollingsworth M, Berman J. The role of androgens in female sexual dysfunction. Sex Reprod Menopause. 2006;4(1):27–32.

    Article  Google Scholar 

  17. Alder J, Zanetti R, Wight E, Urech C, Fink N, Bitzer J. Sexual dysfunction after premenopausal stage I and II breast cancer: do androgens play a role? J Sex Med. 2008;5(8):1898–906.

    Article  PubMed  Google Scholar 

  18. Lutgendorf SK, Anderson B, Rothrock N, Buller RE, Sood AK, Sorosky JI. Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. Cancer. 2000;89(6):1402–11.

    Article  CAS  PubMed  Google Scholar 

  19. Tierney DK. Sexuality: a quality-of-life issue for cancer survivors. Semin Oncol Nurs. 2008;24(2):71–9.

    Article  PubMed  Google Scholar 

  20. Ochsenkühn R, Hermelink K, Clayton AH, et al. Menopausal status in breast cancer patients with past chemotherapy determines long-term hypoactive sexual desire disorder. J Sex Med. 2011;8(5):1486–94.

    Article  PubMed  Google Scholar 

  21. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(5):386–405.

    Article  PubMed  Google Scholar 

  22. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs. 2004;15(8):753–60.

    Article  CAS  PubMed  Google Scholar 

  23. Hawkins Y, Ussher J, Gilbert E, Perz J, Sandoval M, Sundquist K. Changes in sexuality and intimacy after the diagnosis and treatment of cancer: the experience of partners in a sexual relationship with a person with cancer. Cancer Nurs. 2009;32(4):271–80.

    Article  PubMed  Google Scholar 

  24. Gilbert E, Ussher JM, Hawkins Y. Accounts of disruptions to sexuality following cancer: the perspective of informal carers who are partners of a person with cancer. Health. 2009;13(5):523–41.

    Article  PubMed  Google Scholar 

  25. Hodgkinson K, Butow P, Hunt GE, Wyse R, Hobbs KM, Wain G. Life after cancer: couples’ and partners’ psychological adjustment and supportive care needs. Support Care Cancer. 2007;15(4):405–15.

    Article  CAS  PubMed  Google Scholar 

  26. Lopez V, Copp G, Molassiotis A. Male caregivers of patients with breast and gynecologic cancer: experiences from caring for their spouses and partners. Cancer Nurs. 2012;35(6):402–10.

    Article  PubMed  Google Scholar 

  27. Inwald EC, Koller M, Klinkhammer-Schalke M, et al. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry. J Cancer Res Clin Oncol. 2015;141(12):2229–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

    Article  CAS  Google Scholar 

  30. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937–47.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002;20(11):2758–60.

    Article  PubMed  Google Scholar 

  32. Metindir J, Aslan S, Bilir G. Ovarian cyst formation in patients using tamoxifen for breast cancer. Jpn J Clin Oncol. 2005;35(10):607–11.

    Article  PubMed  Google Scholar 

  33. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol. 1999;17(5):1488–92.

    Article  CAS  PubMed  Google Scholar 

  34. Mourits MJ, Böckermann I, de Vries EG, et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer. 2002;86(10):1546–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Safarinejad MR, Shafiei N, Safarinejad S. Quality of life and sexual functioning in young women with early-stage breast cancer 1 year after lumpectomy. Psychooncology. 2013;22(6):1242–8.

    Article  PubMed  Google Scholar 

  36. Berglund G, Nystedt M, Bolund C, Sjödén PO, Rutquist LE. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol. 2001;19(11):2788–96.

    Article  CAS  PubMed  Google Scholar 

  37. Biglia N, Moggio G, Peano E, et al. Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med. 2010;7(5):1891–900.

    Article  PubMed  Google Scholar 

  38. Speer JJ, Hillenberg B, Sugrue DP, et al. Study of sexual functioning determinants in breast cancer survivors. Breast J. 2005;11(6):440–7.

    Article  PubMed  Google Scholar 

  39. Frechette D, Paquet L, Verma S, et al. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. Breast Cancer Res Treat. 2013;141(1):111–7.

    Article  CAS  PubMed  Google Scholar 

  40. Moyer VA, U.S. Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(10):698–708.

    PubMed  Google Scholar 

  41. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337(23):1641–7.

    Article  CAS  PubMed  Google Scholar 

  42. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res. 2010;3(6):696–706.

    Article  CAS  Google Scholar 

  43. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2742–51.

    Article  CAS  PubMed  Google Scholar 

  44. Yang ZD, Yu J, Zhang Q. Effects of raloxifene on cognition, mental health, sleep and sexual function in menopausal women: a systematic review of randomized controlled trials. Maturitas. 2013;75(4):341–8.

    Article  CAS  PubMed  Google Scholar 

  45. Biri A, Korucuoglu U, Ilhan MN, Ciftci B, Bozkurt N, Guner H. Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women. Arch Gynecol Obstet. 2009;279(4):505–9.

    Article  CAS  PubMed  Google Scholar 

  46. Modugno F, Ness RB, Ewing S, Cauley JA. Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis. Obstet Gynecol. 2003;101(2):353–61.

    CAS  PubMed  Google Scholar 

  47. Arimidex T. Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.

    Article  CAS  Google Scholar 

  48. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause. 2013;20(2):162–8.

    PubMed  Google Scholar 

  49. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46.

    Article  PubMed  CAS  Google Scholar 

  50. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Yokosuka K, Teshima H, Katase K, et al. Effects of long-term administration of tamoxifen on vaginal epithelium and complications of endometrial lesions in breast cancer patients. Nihon Sanka Fujinka Gakkai Zasshi. 1995;47(2):125–32.

    CAS  PubMed  Google Scholar 

  52. Ganz PA, Greendale GA, Kahn B, O’Leary JF, Desmond KA. Are older breast carcinoma survivors willing to take hormone replacement therapy? Cancer. 1999;86(5):814–20.

    Article  CAS  PubMed  Google Scholar 

  53. Vavilis D, Zafrakas M, Goulis DG, Pantazis K, Agorastos T, Bontis JN. Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists. Eur J Gynaecol Oncol. 2009;30(1):82–4.

    CAS  PubMed  Google Scholar 

  54. Theriault RL, Sellin RV. A clinical dilemma: estrogen replacement therapy in postmenopausal women with a background of primary breast cancer. Ann Oncol. 1991;2(10):709–17.

    Article  CAS  PubMed  Google Scholar 

  55. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol. 2001;19(8):2357–63.

    Article  CAS  PubMed  Google Scholar 

  56. O’Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93(10):754–62.

    Article  PubMed  Google Scholar 

  57. DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H. Breast cancer survival and hormone replacement therapy: a cohort analysis. Am J Clin Oncol. 2000;23(6):541–5.

    Article  CAS  PubMed  Google Scholar 

  58. Ursic-Vrscaj M, Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol. 1999;25(2):146–51.

    Article  CAS  PubMed  Google Scholar 

  59. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol. 1997;65(1):89–93.

    Article  CAS  PubMed  Google Scholar 

  60. Holmberg L, Anderson H. HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363(9407):453–5.

    Article  CAS  PubMed  Google Scholar 

  61. Holmberg L, Iversen O-E, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475–82.

    Article  CAS  PubMed  Google Scholar 

  62. von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst. 2005;97(7):533–5.

    Article  Google Scholar 

  63. Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2013;49(1):52–9.

    Article  PubMed  CAS  Google Scholar 

  64. Kaunitz AM, Manson JE. Management of menopausal symptoms. Obstet Gynecol. 2015;126(4):859–76.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 126: management of gynecologic issues in women with breast cancer. Obstet Gynecol. 2012;119(3):666–82.

    Article  Google Scholar 

  66. Berga SL. Profile of ospemifene in the breast. Reprod Sci. 2013;20(10):1130–6.

    Article  PubMed  CAS  Google Scholar 

  67. Kangas L, Unkila M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids. 2013;78(12-13):1273–80.

    Article  CAS  PubMed  Google Scholar 

  68. Portman DJ, Bachmann GA, Simon JA, Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(6):623–30.

    Article  PubMed  Google Scholar 

  69. Bachmann GA, Komi JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480–6.

    PubMed  Google Scholar 

  70. Pinkerton JV, Kagan R. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. Expert Opin Pharmacother. 2015;16(17):2703–14.

    Article  CAS  PubMed  Google Scholar 

  71. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001;76(1-5):231–8.

    Article  CAS  PubMed  Google Scholar 

  72. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric. 2001;4(1):28–41.

    Article  CAS  PubMed  Google Scholar 

  73. Kenemans P, Bundred NJ, Foidart J-M, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009;10(2):135–46.

    Article  CAS  PubMed  Google Scholar 

  74. Lee K-B, Lee J-M, Lee J-K, Cho C-H. Endometrial cancer patients and tibolone: a matched case-control study. Maturitas. 2006;55(3):264–9.

    Article  CAS  PubMed  Google Scholar 

  75. Al-Baghdadi O, Ewies AAA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric. 2009;12(2):91–105.

    Article  CAS  PubMed  Google Scholar 

  76. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2003;(4):CD001500.

    Google Scholar 

  77. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency – a pharmacokinetic and pharmacodynamic study. Maturitas. 1992;15(2):121–7.

    Article  CAS  PubMed  Google Scholar 

  78. Vooijs GP, Geurts TB. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol. 1995;62(1):101–6.

    Article  CAS  PubMed  Google Scholar 

  79. Le Ray I, Dell’Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135(2):603–9.

    Article  PubMed  CAS  Google Scholar 

  80. Moegele M, Buchholz S, Seitz S, Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet. 2012;285(5):1397–402.

    Article  CAS  PubMed  Google Scholar 

  81. Committee Opinion No. 659 Summary: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):618–9.

    Google Scholar 

  82. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23(3):259–63.

    Article  CAS  PubMed  Google Scholar 

  83. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Bø K. Pelvic floor muscle training in treatment of female stress urinary incontinence, pelvic organ prolapse and sexual dysfunction. World J Urol. 2012;30(4):437–43.

    Article  PubMed  Google Scholar 

  85. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.

    PubMed  Google Scholar 

  86. Dumoulin C, Hay-Smith EJC, Mac Habée-Séguin G. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2014;(5):CD005654.

    Google Scholar 

  87. Rosenbaum TY. Pelvic floor involvement in male and female sexual dysfunction and the role of pelvic floor rehabilitation in treatment: a literature review. J Sex Med. 2007;4(1):4–13.

    Article  PubMed  Google Scholar 

  88. Juraskova I, Jarvis S, Mok K, et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J Sex Med. 2013;10(10):2549–58.

    Article  PubMed  Google Scholar 

  89. Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med. 2011;8(2):549–59.

    Article  PubMed  Google Scholar 

  90. Wanchai A, Armer JM, Stewart BR. Complementary and alternative medicine use among women with breast cancer: a systematic review. Clin J Oncol Nurs. 2010;14(4):E45–55.

    Article  PubMed  Google Scholar 

  91. Naja F, Fadel RA, Alameddine M, et al. Complementary and alternative medicine use and its association with quality of life among Lebanese breast cancer patients: a cross-sectional study. BMC Complement Altern Med. 2015;15(1):444.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Brzezinski A, Debi A. Phytoestrogens: the “natural” selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol. 1999;85(1):47–51.

    Article  CAS  PubMed  Google Scholar 

  93. Patisaul HB, Jefferson W. The pros and cons of phytoestrogens. Front Neuroendocrinol. 2010;31(4):400–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295(17):2057–71.

    Article  CAS  PubMed  Google Scholar 

  95. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;(12):CD001395.

    Google Scholar 

  96. Taylor CK, Levy RM, Elliott JC, Burnett BP. The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev. 2009;67(7):398–415.

    Article  PubMed  Google Scholar 

  97. Bouker KB, Hilakivi-Clarke L. Genistein: does it prevent or promote breast cancer? Environ Health Perspect. 2000;108(8):701–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Palacio C, Masri G, Mooradian AD. Black cohosh for the management of menopausal symptoms: a systematic review of clinical trials. Drugs Aging. 2009;26(1):23–36.

    Article  CAS  PubMed  Google Scholar 

  99. Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin H-H. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol. 2005;105(5 Pt 1):1074–83.

    Article  PubMed  Google Scholar 

  100. Wuttke W, Seidlová-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas. 2003;44 Suppl 1:S67–77.

    Article  PubMed  Google Scholar 

  101. Rostock M, Fischer J, Mumm A, Stammwitz U, Saller R, Bartsch HH. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints – a prospective observational study. Gynecol Endocrinol. 2011;27(10):844–8.

    Article  CAS  PubMed  Google Scholar 

  102. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001;19(10):2739–45.

    Article  CAS  PubMed  Google Scholar 

  103. Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol. 2005;4(3):177–84.

    Article  PubMed  Google Scholar 

  104. Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause. 2010;17(2):426–40.

    Article  PubMed  Google Scholar 

  105. Uebelhack R, Blohmer J-U, Graubaum H-J, Busch R, Gruenwald J, Wernecke K-D. Black cohosh and St. John’s wort for climacteric complaints: a randomized trial. Obstet Gynecol. 2006;107(2 Pt 1):247–55.

    Article  PubMed  Google Scholar 

  106. Chung D-J, Kim H-Y, Park K-H, et al. Black cohosh and St. John’s wort (GYNO-Plus) for climacteric symptoms. Yonsei Med J. 2007;48(2):289–94.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause. 2008;15(1):51–8.

    PubMed  Google Scholar 

  108. Calapai G. European legislation on herbal medicines: a look into the future. Drug Saf. 2008;31(5):428–31.

    Article  PubMed  Google Scholar 

  109. Mehta DH, Gardiner PM, Phillips RS, McCarthy EP. Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med. 2008;14(10):1263–9.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20(6):1578–83.

    Article  CAS  PubMed  Google Scholar 

  111. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356(9247):2059–63.

    Article  CAS  PubMed  Google Scholar 

  112. Margolese HC, Assalian P. Sexual side effects of antidepressants: a review. J Sex Marital Ther. 1996;22(3):209–17.

    Article  CAS  PubMed  Google Scholar 

  113. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259–66.

    Article  CAS  PubMed  Google Scholar 

  114. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305(3):267–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Reed SD, Guthrie KA, Joffe H, Shifren JL, Seguin RA, Freeman EW. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2012;119(3):527–38.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Perez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol. 2004;2(1):50–6.

    CAS  PubMed  Google Scholar 

  117. Pérez DG, Loprinzi CL, Sloan J, et al. Pilot evaluation of bupropion for the treatment of hot flashes. J Palliat Med. 2006;9(3):631–7.

    Article  PubMed  Google Scholar 

  118. Ahmad K. Antidepressants may decrease tamoxifen efficacy. Lancet Oncol. 2004;5(1):6.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale University School of Medicine/Yale New Haven Hospital, New Haven, CT, USA

    Eve Overton

  2. Department of Medical Oncology, Yale New Haven Hospital, 333 Cedar Street, 208063, New Haven, CT, 06520-8063, USA

    Erin Hofstatter

  3. Department of Obstetrics and Gynecology, Yale New Haven Hospital, 333 Cedar Street, 208063, New Haven, CT, 06520-8063, USA

    Devin Miller & Elena Ratner

Authors
  1. Eve Overton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erin Hofstatter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Devin Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elena Ratner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eve Overton .

Editor information

Editors and Affiliations

  1. Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Reproductive Endocrinology and Infertility Yale School of Medicine, New Haven, Connecticut, USA

    Lubna Pal

  2. Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, Massachusetts, USA

    Raja A. Sayegh

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Overton, E., Hofstatter, E., Miller, D., Ratner, E. (2017). Management Strategies for Sexual Health After Breast Cancer Diagnosis. In: Pal, L., Sayegh, R. (eds) Essentials of Menopause Management. Springer, Cham. https://doi.org/10.1007/978-3-319-42451-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42451-4_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42449-1

  • Online ISBN: 978-3-319-42451-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation